CU6
Hi James, Shawn and the Team, Thanks a lot for answering my questions and providing valuable feedback. I would like to know your latest opinion on CU6. CU’’s share price dropped from a high of $8.80 on 2/Oct to $6.35 today (15/10) – a drop of almost 30% in about 10 days. Within this short time, CU6 made two positive announcements – Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA, and Positive guidance from US FDA on Phase III trial. In the US FDA announcement, it was mentioned that “Patient recruitment for the AMPLIFY trial is expected to commence in early 2025”. Is it because the market thinks that the approval from FDA would take another 6 to 9 months after patient recruitment; and in the meantime CU6 does not generate Sales Revenue. The market may think CU6 may need to raise cash with the shareholders.
